Could an optimized joint pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam be a way to avoid the need for combo therapy in the targeted treatment of deep-seated DTR Gram-negative infections?

The objective of this study was to assess the relationship between joint pharmacokinetic/pharmacodynamic (PK/PD) target attainment of continuous infusion (CI) ceftazidime-avibactam and the microbiological outcome of documented difficult-to-treat resistant (DTR) Gram-negative infections. A 2-year ret...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Antimicrobial agents and chemotherapy 2023-11, Vol.67 (11), p.e0096923-e0096923
Hauptverfasser:	Gatti, Milo, Rinaldi, Matteo, Bonazzetti, Cecilia, Gaibani, Paolo, Giannella, Maddalena, Viale, Pierluigi, Pea, Federico
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - pharmacology Azabicyclo Compounds - pharmacology Ceftazidime - pharmacology Drug Combinations Humans Microbial Sensitivity Tests Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!